WO2012021788A3 - Dipeptide calpain inhibitors - Google Patents

Dipeptide calpain inhibitors Download PDF

Info

Publication number
WO2012021788A3
WO2012021788A3 PCT/US2011/047560 US2011047560W WO2012021788A3 WO 2012021788 A3 WO2012021788 A3 WO 2012021788A3 US 2011047560 W US2011047560 W US 2011047560W WO 2012021788 A3 WO2012021788 A3 WO 2012021788A3
Authority
WO
WIPO (PCT)
Prior art keywords
calpain inhibitors
dipeptide
useful
compounds
neural
Prior art date
Application number
PCT/US2011/047560
Other languages
French (fr)
Other versions
WO2012021788A2 (en
Inventor
Kevin Ka-Wang Wang
Zhiqun Zhang
Xue-Min Cheng
Bradley Caprathe
Original Assignee
Banyan Biomarkers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyan Biomarkers filed Critical Banyan Biomarkers
Publication of WO2012021788A2 publication Critical patent/WO2012021788A2/en
Publication of WO2012021788A3 publication Critical patent/WO2012021788A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compounds, pharmaceutically acceptable salts thereof, and compositions useful as calpain inhibitors are disclosed. Certain compounds are also useful for the treatment of acute or chronic neurodegenerative disorders. Other compounds are useful as neural and organ-specific imaging agents.
PCT/US2011/047560 2010-08-13 2011-08-12 Dipeptide calpain inhibitors WO2012021788A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37369310P 2010-08-13 2010-08-13
US61/373,693 2010-08-13

Publications (2)

Publication Number Publication Date
WO2012021788A2 WO2012021788A2 (en) 2012-02-16
WO2012021788A3 true WO2012021788A3 (en) 2012-08-09

Family

ID=45568211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/047560 WO2012021788A2 (en) 2010-08-13 2011-08-12 Dipeptide calpain inhibitors

Country Status (1)

Country Link
WO (1) WO2012021788A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642558B2 (en) 2008-09-19 2014-02-04 Henry Ford Health Systems Methods, systems, and compositions for calpain inhabition
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
SG10201912574WA (en) 2016-09-28 2020-02-27 Blade Therapeutics Inc Calpain modulators and therapeutic uses thereof
EP3564211A1 (en) * 2018-05-03 2019-11-06 Landsteiner Genmed, S.L. Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof
WO2023249007A1 (en) * 2022-06-23 2023-12-28 五稜化薬株式会社 Calpain inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016767A1 (en) * 1998-09-22 2000-03-30 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000016767A1 (en) * 1998-09-22 2000-03-30 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LESCOP, CYRILLE ET AL.: "Novel cell-penetrating a-keto-amide calpain inhibi tors as potential tretment for muscular dystrophy.", BIOORGANIC & MEDICAL CHEMISTRY LETTERS., vol. 15, 2005, pages 5176 - 5181 *
ZENG, YIBIN ET AL.: "Synthesis of a small library of diketopiperazines as potential inhibitors of calpain.", BIOORGANIC & MEDICAL CHEMISTRY LETTERS., vol. 15, 2005, pages 3034 - 3038 *

Also Published As

Publication number Publication date
WO2012021788A2 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
HK1216615A1 (en) Compositions and methods for the treatment or the prevention oral infections by e. coli
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2008039520A3 (en) Fused ring compounds for inflammation and immune-related uses
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
WO2014055996A3 (en) Rho kinase inhibitors
WO2010039237A8 (en) Compounds for inflammation and immune-related uses
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2011069063A3 (en) Multicyclic compounds and methods of use thereof
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
WO2009120810A3 (en) Neurodegenerative disorders
TW200731974A (en) Transdermal system for verenicline
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2012021788A3 (en) Dipeptide calpain inhibitors
MX370253B (en) Compositions of jasmonate compounds and methods of use.
WO2012082862A3 (en) Androgen receptor inhibitors and methods of use thereof
WO2012021800A3 (en) Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2013016205A3 (en) Compositions and methods for reducing the incidence of equine digestive disorders
EP2572721A4 (en) Pharmaceutical composition including an hif-2 inhibitor as an active ingredient for preventing or treating arthritis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11817094

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11817094

Country of ref document: EP

Kind code of ref document: A2